[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proximal-transverse-colon-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proximal-transverse-colon-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100510193","lish-trial-for-the-hepatic-flexure-and-proximal-transverse-colon-cancer-100510193",false,"NCT05923255","LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer","Laparoscopic Ileocecal-Sparing Right Hemicolectomy for Cancer of the Hepatic Flexure and Proximal Transverse Colon -- A Prospective, Multicenter Randomized Control Clinical Trial","Inclusion Criteria:\n\n1. Age between 18-75 years old\n2. ASA classification ≤III\n3. Colon adenocarcinoma confirmed by endoscopy and pathological biopsy\n4. Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1\u002F3 of the transverse colon)\n5. Preoperative clinical staging: TanyNanyM0\n6. Patients able to understand the study protocol, willing to participate in the research, and providing written informed consent\n\nExclusion Criteria:\n\n1. Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection\n2. Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of distant metastasis; 3) inability to perform R0 resection; 4) fused and fixed lymph nodes at the root of the ileocolic vessels\n3. Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures\n4. History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell carcinoma, papillary thyroid carcinoma, or skin squamous cell carcinoma\n5. Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery\n6. Patients unsuitable for or unable to tolerate laparoscopic surgery\n7. Pregnant or lactating women\n8. Patients with a history of psychiatric disorders\n9. Patients who have received neoadjuvant therapy prior to surgery\n10. Patients deemed unsuitable for the study by MDT discussion\n11. Patients unable to understand the study's conditions and objectives, and refusing to sign informed consent.","ALL","18 Years","75 Years",{"count":20,"type":21},568,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the long-term outcomes of Laparoscopic Ileocecal-Sparing Right Hemicolectomy(LISH) compared to traditional laparoscopic right hemicolectomy(TRH) in the treatment of hepatic flexure colon cancer and proximal transverse colon cancer.",[27,28],"Hepatic Flexure Colon Cancer","Proximal Transverse Colon Cancer",[30,31,32,33],"hepatic flexure colon cancer","proximal transverse colon cancer","ileocecus-sparing","laparoscopic right hemicolectomy","RECRUITING","2026-01-25",{"date":37,"type":38},"2026-01-27","ACTUAL",{"date":40,"type":38},"2023-05-14",{"date":42,"type":21},"2031-05-14",{"name":44,"class":45},"Zhejiang University","OTHER",29,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100608881","lirrh-trial-for-the-right-sided-colon-cancer-100608881","NCT07207317","LIRRH Trial for the Right-sided Colon Cancer","Laparoscopic Ileocecal Reconstruction Right Hemicolectomy (LIRRH) Trial for the Right-sided Colon Cancer","LIRRH","Inclusion Criteria:\n\n* Age 18-75 years\n* ASA physical status ≤ III\n* Endoscopy and biopsy-proven colon adenocarcinoma\n* Contrast-enhanced abdominal CT showing primary tumor located in the ascending colon or proximal transverse colon (proximal one-third)\n* Pre-operative clinical stage: TanyNanyM0\n* Able to understand the study protocol, willing to participate, and provide written informed consent\n\nExclusion Criteria:\n\n* History of hypertensive crisis or hypertensive encephalopathy.\n* Severe cardiopulmonary insufficiency or any other contraindication to surgery.\n* Uncorrectable electrolyte disturbances (e.g., potassium, calcium, magnesium).\n* Evidence of significant bleeding diathesis or high hemorrhagic risk:\n* Prior intracranial or intraspinal hemorrhage.\n* Tumor invading major vessels with obvious bleeding risk.\n* Thrombotic or embolic event within 6 months before study treatment, or significant vascular disease (e.g., surgical-repair aortic aneurysm).\n* Clinically relevant hemoptysis or tumor bleeding of any cause within 1 month before screening.\n* Therapeutic-dose anticoagulation within 2 weeks before study treatment (except low-molecular-weight heparin).\n* Antiplatelet therapy within 10 days before study treatment (e.g., aspirin \\> 325 mg\u002Fday, clopidogrel \\> 75 mg\u002Fday, dipyridamole, ticlopidine, cilostazol).\n* Active tuberculosis.\n* Any active autoimmune disease or history of autoimmune disease with expected recurrence (including but not limited to SLE, RA, autoimmune hepatitis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyper- or hypothyroidism, asthma requiring bronchodilators).\n* Pre-operative evidence of synchronous multiple primary colorectal cancers or other conditions requiring additional bowel resection.\n* Pre-operative imaging or intra-operative findings showing:\n* Tumor infiltration into adjacent organs requiring multi-visceral resection;\n* Distant metastasis;\n* Unresectable (unable to achieve R0) disease.\n* Other malignancies within the past 5 years, or familial adenomatous polyposis; except cured carcinoma in situ of the cervix, basal-cell carcinoma, papillary thyroid carcinoma, or cutaneous squamous-cell carcinoma.\n* Intestinal obstruction, perforation, or bleeding requiring emergency surgery.\n* Patient unsuitable or unable to tolerate laparoscopic surgery.\n* Pregnant or lactating women.\n* History of psychiatric disorders precluding compliance.\n* Prior neoadjuvant therapy.\n* Multidisciplinary team (MDT) decision that the patient is not appropriate for the study.\n* Patient unable to understand the study conditions\u002Fobjectives and refuses to give informed consent.",{"count":56,"type":21},120,[24],"The aim of this clinical trial is to compare the short- and long-term outcomes of laparoscopic ileocecal reconstruction right hemicolectomy (LIRRH) with those of traditional laparoscopic right hemicolectomy (TRH) for ascending and proximal transverse colon cancer.",[60,28],"Ascending Colon Cancer",[62,63,64,65,66,67,53],"Right-sided colon cancer","Laparoscopic right hemicolectomy","Ileocecal reconstruction","Randomized controlled trial","Disease-free survival","TRH","2025-09-28",{"date":70,"type":38},"2025-10-03",{"date":72,"type":38},"2025-05-01",{"date":74,"type":21},"2028-04-28",{"name":76,"class":45},"Chaoxi Zhou",1]